Dell Medical School

XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy

Retrieved on: 
Tuesday, January 19, 2021
Dell Medical School, Medical education in the United States, University of Texas System, Clay Johnston, Stroke, Cerebrovascular disease, Education in the United States, Higher education in the United States

AUSTIN, Texas, Jan. 19, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today the first meeting of its Cerebrovascular Medical Advisory Board (CMAB).

Key Points: 
  • AUSTIN, Texas, Jan. 19, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today the first meeting of its Cerebrovascular Medical Advisory Board (CMAB).
  • The CMAB is providing expert Medical and Clinical guidance for XBiotechs new candidate neuroprotectant, anti-inflammatory True Human antibody therapy to treat stroke.
  • XBiotechs Cerebrovascular Medical Advisory Board Includes:
    Clay Johnston M.D., Ph.D. currently serves as the inaugural dean of Dell Medical School at the University of Texas in Austin.
  • is a stroke and vascular neurologist and currently serves as the Director of the Stanford Stroke Center at Stanford Medical Center.